TNFRSF8 and post-transplant lymphoproliferative disease: That is, the immunophenotype for CHL-type PTLD is CD15+, CD20−, CD30+, CD45− and PAX5 weak+, whereas the immunophenotype for polymorphic PTLD with HRS-like cells is usually CD15−, CD20+ and CD45+.